Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 3Phase 3 2Phase 1 1

Status

Completed 6Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 118Specimen Handling 104pembrolizumab 103Magnetic Resonance Spectroscopy 95fludarabine 93Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 37Paclitaxel 35Cetuximab 35Carboplatin 35Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Gemcitabine 29Leucovorin 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20130-nm albumin-bound paclitaxel 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Inotuzumab Ozogamicin × Clear all
NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Children's Hospital Medical Center, Cincinnati

Phase 1 Recruiting
28 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡